Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Dec 30, 2025 | Benefits preservation, Biosimilars, Client Feedback, Client Surveys, Direct-to-Employer Contracting, Forensic claims review, Innovations, Kurt Harden, MedBen Employees, Self-funding, Spending, Third party administration
On behalf of the MedBen team, I wish you a happy and healthy new year, and thank you for your continued trust in MedBen. Our commitment remains to be the benefits partner that employers prefer, and we value the opportunity to serve you. In my 35 years with MedBen,...
Oct 21, 2025 | biologics, Biosimilars, Cost Savings, Humira, Rx Costs, Savings, Stelara
To help clients more efficiently access the cost savings of biosimilars, MedBen Rx is introducing an advance notice model. Rather than requiring approval each time a new biosimilar becomes available, this proactive approach automatically adds new biosimilars to your...
Jul 29, 2025 | biologics, Biosimilars, Cost Savings, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Prescription, Rx Costs, Savings
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....
May 19, 2025 | Biosimilars, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
Apr 21, 2025 | Biosimilars, Cost Savings, Drug costs, Rx Costs, Savings, Stelara
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
